Duke is the Lead Site for Atmosphere and Ascent Trials

Duke is the lead site and Lejla Vajzovic, MD is the lead PI for the Duke site. Atmosphere and Ascent are pivotal trials are expected to support Biologics License Application (BLA) submission for RGX-314 in 2024. Both are phase III clinical trials aiming to develop RGX-314 as a one-time gene therapy for the treatment of wet AMD. Wet AMD is a significant cause of vision loss, so the positive results of these trials would lead to treatment for those with Wet AMD and other difficult to treat retinal diseases.